ERBB2 and endometrial carcinoma: The Gynecologic Oncology Group (GOG) published data from a large cohort of patients with advanced or recurrent endometrial carcinomas; among the patients with USC tumors, 61% were found to have HER2 overexpression by IHC staining, and only 21% were found to have HER2 gene amplification by FISH [14].